Abstract Library

#4219 MAPK and mTOR pathway activation is associated with chemotherapy resistance and a poor prognosis in G3 advanced NENs

Introduction: Neuroendocrine neoplasms (NENs) comprise a broad spectrum of disease ranging from slowly progressive to highly aggressive carcinomas.

Conference:

Presenting Author: Catoya J

Authors: Catoya J, Anton-Pascual B, Farinea G, Modrego A, La Salvia A,

Keywords: NEN, mTOR/MAPK pathway, molecular profiling, platinum-based,

#4205 Precision medicine in advanced NENs: Molecular profiling and target actionability real world data

Introduction: Molecular profiling (MP) of NENs is not performed on routine basis and its potential clinical use is a matter of debate.

Conference:

Presenting Author: Farinea G

Authors: Farinea G, Anton-Pascual B, Catoya J, Modrego A, La Salvia A,

Keywords: Genomic Profiling, ESCAT, NEN, Precision Medicine,

#4200 Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,

#4137 Liquid biopsy as a new tool for the molecular profiling of neuroendocrine neoplasms: The Gustave Roussy experience

Introduction: Molecular profiling (MP) in neuroendocrine neoplasm (NEN) tumor tissue may be useful for precision medicine. Liquid biopsy (LB) is an alternative noninvasive strategy to perform MP.

Conference:

Presenting Author:

Authors: Gagliardi I, Boilève A, Fodil-Cherif S, Moog S, Lamartina L,

Keywords: neuroendocrine tumor, neuroendocrine carcinoma, molecular profile, liquid biopsy, clonal hematopoiesis,

#3963 Infrastructure FOr Rare Cancer in the NEtherlands, towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE), and especially neuroendocrine neoplasms (NEN)

Introduction: NEN consist of a heterogeneous group of rare tumors. For these patients, clinical trials requiring a high number of patients are often infeasible. Often, the prognosis is poor due to late diagnosis and fewer available treatment options as compared to patients with common cancer types. In common cancers, ultrasensitive molecular profiling of circulating cell-free DNA (USccfDNA) based tests are promising to improve diagnosis, detection of minimal residual disease (MRD), and recurrence. Data needed to apply USccfDNA in NEN is lacking.

Conference:

Presenting Author:

Authors: de Hosson L, Pieterman C, Fehrmann R, de Herder W, Jalving M,

Keywords: circulating cell free DNA, biobank, databank, early detection,